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Abstract Expressing proteins with fusion partners improves
yield and simplifies the purification process. We developed a
novel fusion partner to improve the secretion of heterologous
proteins that are otherwise poorly excreted in yeast. The VOA1
(YGR106C) gene of Saccharomyces cerevisiae encodes a
subunit of vacuolar ATPase. We found that C-terminally trun-
cated Voa1p was highly secreted into the culture medium,
even when fused with rarely secreted heterologous proteins
such as human interleukin-2 (hIL-2). Deletion mapping of C-
terminally truncated Voa1p, identified a hydrophilic 28-amino
acid peptide (HL peptide) that was responsible for the en-
hanced secretion of target protein. A purification tag and a
protease cleavage site were added to use HL peptide as a
multi-purpose fusion partner. The utility of this system was
tested via the expression and purification of various heterolo-
gous proteins. In many cases, the yield of target proteins fused
with the peptide was significantly increased, and fusion pro-
teins could be directly purified with affinity chromatography.
The fusion partner was removed by in vitro processing, and
intact proteins were purified by re-application of samples to
affinity chromatography.
Keywords Saccharomyces cerevisiae .VOA1 . Fusion
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Introduction
Owing to its generally recognized as safe (GRAS) status, the
yeast Saccharomyces cerevisiae has been widely used as a pop-
ular workhorse for the production of various pharmaceutical and
industrial proteins. The yeast expression system combines the
advantages of both bacteria and higher eukaryotic cells (Kunes
et al. 1987). It is a eukaryotic microorganism that can be cultured
at high cell density, which facilitates large-scale fermentation.
Additionally, the yeast protein secretion pathway and post-
translational modification systems are similar to those of higher
eukaryotic cells, although the fidelity of protein hyper-
glycosylation varies according to the specific target (Buckholz
and Gleeson 1991). Thus, yeast can produce various complex
proteins that are native to higher eukaryotes including humans;
this is a distinct advantage over production inEscherichia coli, as
proteins lack eukaryotic modifications and are often inactive.
Furthermore, secretory production of foreign proteins greatly
simplifies the purification procedure and reduces the production
cost compared to intracellular production.
Secretory production of heterologous protein involves the se-
quential processes of protein synthesis, folding and secretory
trafficking. The secretion rate of overexpressed proteins ismainly
dependent on the folding rate in the endoplasmic reticulum (ER)
(Robinson and Wittrup 1995). Unless they fold correctly, these
proteins accumulate in the ER as aggregates; this triggers the
unfolded protein response and eventual degradation of proteins
by an ER-associated degradation pathway (Ellgaard and
Helenius 2003). Numerous approaches have been applied to
enhance protein-folding rate and avoid aggregation and degrada-
tion. These include overexpression of molecular chaperones,
foldases (Hackel et al. 2006),(Powers and Robinson 2007), and
genes related to the secretory pathway (Carla Fama et al. 2007),
(Wentz and Shusta 2007) and engineering of the leader sequence
(Clements et al. 1991),(Kjaerulff and Jensen 2005).
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Another way to increase protein secretion is by direct fusion
of the target protein to well-secreted proteins such as human
serum albumin (Kang et al. 2007), (Huang et al. 2008) protein
disulfide isomerase (Kajino et al. 2000), Hsp150 protein (Sievi
et al. 2003), cellulose-binding domain (Ahn et al. 2004) and cell
wall protein Pir4 (Andres et al. 2005). The secretion-enhancing
effects of such fusions are often attributed to the improved sta-
bility and transport of target proteins.
We previously developed a translational fusion partner (TFP)
technology that provides optimal fusion partners for secretory
production of otherwise poorly secreted proteins in yeast (Bae
et al. 2015). In the course of TFP screening from yeast genome,
we discovered that the VOA1 protein was abundantly secreted
into extracellular medium when the C-terminal transmembrane
domain was deleted and overexpressed under the control of the
strong promoter.
In this study, we engineered C-terminally truncated Voa1p for
use as a multi-functional fusion partner for secretory production
of foreign proteins in yeast. Using a series of deletion variants,
we found that a domain of Voa1p comprised of 28 hydrophilic
amino acids (HL domain) was sufficient to enhance protein se-
cretion. Consequently, we performed additional engineering to
add a purification tag and protease cleavage site to the HL do-
main; this facilitated both the expression and purification of var-
ious heterologous proteins.
Methods
Strains and growth conditionsHaploid yeast Saccharomyces
cerevisiae Y2805 (Mat α pep4::HIS3 prb1 can1 his3-200
ura3-52) (Choi et al. 1994) was used as the general host for
gene expression. All yeast transformations were performed
using the lithium acetate method (Gietz et al. 1995). Yeast were
generally grown onYPD (1% yeast extract, 2% bacto peptone,
and 2 % glucose). General selection of yeast transformants was
performed using a UD plate media (0.67 % yeast nitrogen base
without amino acids, 2 % glucose, 0.5 % casamino acids, and
2% agar). Recombinant yeast strains were cultivated on YPDG
(1 % yeast extract, 2 % bacto peptone, 1 % glucose, and 1 %
galactose) to induce GAL10 promoter in the Y2805 strain. For
the fermentation of recombinant strains, a seed culture was
prepared using UD broth, and transferred to a 1000-ml
Erlenmeyer flask containing 200 ml of UD broth and incubated
in shaking incubator for overnight at 30 °C. The cultured seed
(200 ml) was inoculated into a 5-l jar fermenter (Kobiotech,
Seoul, Korea) containing 1800 ml of fermentation medium
(4 % yeast extract, 1 % bacto peptone, and 2 % of glucose).
When glucose was completely exhausted, a feeding medium
containing 300 g of glucose, 300 g of galactose, and 150 g of
yeast extract (per liter) was added. The hourly feeding rate was
manually increased from 2 to 10 g/l of carbon source according
to cell growth. Ammonia solution was used to maintain the
fermentation at pH 5.5. E. coli DH5α [F− lacZΔM15
hsdR17(r- m-) gyrA36] was used for general recombinant
DNA procedures.
Vector construction The primers used in this study are sum-
marized in Table 1. To construct the plasmid YGaT41, which
contains an intact VOA1 gene under the control of the GAL10
promoter, the open reading frame (ORF) of VOA1 was ampli-
fied from S. cerevisiaeY2805 genomic DNAwith polymerase
chain reaction (PCR) primers, a sense primer (T4F) containing
a BamHI site, and an antisense primer (T41R) containing a
SalI site. The amplified VOA1 ORF was digested with
BamHI-SalI and sub-cloned into the BamHI-SalI sites of
YEGα-HIR525 (Choi et al. 1994). To construct incremental
C-terminally truncated VOA1 gene expression vectors, four
antisense primers (T42R–T45R) were designed and used to
amplify VOA1 variants in combination with the T4F primer.
The amplified partial VOA1 gene fragments were cloned into
the BamHI-SalI site of YGaT41 and the resulting plasmids
were named YGaT42, 43, 44, and 45.
To fuse the human interleukin-2 (hIL2) gene to the truncat-
ed VOA1 construct in YGaT42, the partial VOA1 gene was
amplified with a sense primer (GAL100) recognizing the
GAL10 promoter and an antisense primer (H121) that recog-
nizes sequences in the YGaT42 vector. The hIL2 gene was
amplified with sense primer IL2F, which recognizes se-
quences in the VOA1 gene that are complementary to those
of the H121 primer, and an antisense primer (IL2R) that con-
tains part of the GAL7 terminator sequence. The amplified
PCR fragments were annealed to a single fragment by
overlap-extension PCR using GAL100 and GT50R primers.
GT50R primer runs in the antisense direction and contains 50
nucleotides of GAL7 terminator sequence. The resulting PCR
product was flanked with 100 bp of GAL10 promoter se-
quence and 50 bp of GAL7 terminator sequence. The recom-
binant S. cerevisiae Y2805 strain was directly constructed by
co-transformation with the fused PCR product and BamHI-
SalI-digested YGaT41 vector backbone. Circular topology
of plasmid is restored in host cells by homologous recombi-
nation of a linearized vector with a DNA fragment that con-
tains sequences that overlapping sequences at each end
(Kunes et al. 1987). The resulting plasmid was named
YGaT42-IL2. To construct an S. cerevisiae Y2805 strain
transformed with YGaT43-IL2 and YGaT44-IL2 vectors,
H120 and H119 primers were used instead of H121 primer.
The YEGα-EGF plasmid was constructed by subcloning a
chemically synthesized hEGF gene (sequence derived from
a public database, www.ncbi.nlm.nih.gov/genbank) into the
XbaI and SalI sites of the YEGα-HIR525 plasmid. To con-
struct YEGα-HL50-EGF plasmid, the MFα pre-pro peptide
gene, the HL peptide gene, and hEGF were amplified from
YEGα-HIR525, YGaT41, and YEGα-EGF with GAL100
/LNK-R, H221/HDK-R, and H410/GT50R primer sets,
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respectively. These fragments contain 17 or 18 overlapping
nucleotides in order to facilitate their contiguous assembly.
Using overlap-extension PCR with the GAL100/GT50R
primer set, the order of the resulting single fragment was:
MFα pre-pro peptide-HL peptide-hEGF. To construct the
YEGα-EGF-HL plasmid, the HL peptide gene was amplified
with the HL-F/HL-GT50R primer set, and hEGF was ampli-
fied with the H616/H617 primer set. These fragments were
fused with the MFα pre-pro peptide coding sequence that was
amplified with the GAL100/LNK-R primer set. Using
overlap-extension PCR with the GAL100/GT50R primer
set, the order of the single fragment was MFα pre-pro pep-
tide-hEGF-HL. Recombinant S. cerevisiae Y2805 strains
transformed with YEGα-HL50-EGF or YEGα-EGF-HL50
were directly constructed by co-transformation with the fused
PCR products and EcoRI/SalI-digested YEGα-EGF vector
backbone. YEGα-EGF, YEGα-HL50-EGF, and YEGα-
E G F - H L 5 0 v e c t o r s c o n t a i n l i n k e r p e p t i d e
(AASASAGLALDKR) following the MFα pre-pro peptide.
To construct the YEGα-HL37-EGF plasmid, the MFα-HL
peptide coding sequence was amplified with the GAL100
/H618 primer set, and the hEGF gene was amplified from
YEGα-HL50-EGF plasmid with the H619/GT50R primer
set. These fragments were fused with overlap-extension PCR
using the GAL100/GT50R primer set and then cloned into the
EcoRI/SalI sites of YEGα-HL50-EGF. TheMFα pre-pro pep-
tide coding sequence amplified with the GAL100/H620 prim-
er set and the HL-hEGF gene amplified with H621/GT50R
primer set from YEGα-HL37-EGF plasmid, were fused using
overlap-extension PCR with the GAL100/GT50R primer set.
This product was then cloned into the EcoRI/SalI sites of
YEGα-HL50-EGF to make YEGα-HL28-EGF. YEGα-
HL28-EXD4 and YEGα-HL28-IGF plasmids were construct-
ed by replacing the hEGF gene of YEGα-HL28-EGF plasmid
with each gene synthesized at Bioneer (Daejeon, Korea) by
in vivo recombination.
Protein analysis and purification To analyze the secreted
proteins in test tube culture, recombinant cells containing a
foreign protein expression vector were cultivated in 3 ml of
YPDG broth media for 40 h at 30 °C and then 0.6 ml of culture
supernatant was mixed with 0.4 ml of cold acetone. After a 2-
h incubation at −20 °C, proteins were precipitated by centri-
fugation for 15 min at 10,000×g. The pellet was freeze-dried
and resuspended in 1× SDS-PAGE sample buffer (Bio-Rad,
Hercules, CA, USA) and run on 10–12 % of Tris-glycine or
Tricine gels under denaturing conditions. To analyze the se-
creted proteins from fed-batch fermentation, 5–10 μl of cul-
ture supernatant was directly used for SDS-PAGE after
mixing with 2× SDS-PAGE sample buffer, and then stained
with Coomassie blue. Total intracellular yeast protein was
prepared from the cells by post-alkaline extraction (Bae
et al. 2015). A polyclonal antibody to hIL-2 (R&D Systems
Inc., Minneapolis, MN, USA) and an anti-goat IgG alkaline
phosphatase conjugate (Sigma Chemical Co., St. Louis, MO,
USA) was used for western blot analysis. hEGF protein fused
Table 1 Summary of primers
used for plasmid construction Primer Sequence
T4F ATCGGATCCATGGTGTTCGGTCAGCTG
GAL100 GTATATGGTGGTAATGCCATG
GT50R GTCATTATTAAATATATATATATATATATTGTCACTCCGTTCAAGTCGAC
IL2F CTCGCCTTAGATAAAAGAGCACCTACTTCAAGTTCTAC
IL2R GTCACTCCGTTCAAGTCGACCTAAGTTAGTGTTGAGATG
LNK-R CTTTTATCTAAGGCGAGGCCAGCAGAGGCCGAGGCGGCCACCCCTTCTTCTTTA
HDK-R GTCATCGTCACCGTGGTGATGGTGATGATGGCTCAAAGTCTCTT
HL-F GTTATTAACTCTCTTGGTTG
HL-GT50R CACTCCGTTCAAGTCGACTTAGTGGTGATGGTGATGATGG
H119 TCTTTTATCTAAGGCGAGAAAAGCCCAACCAAGAG
H120 TCTTTTATCTAAGGCGAGCTCTTCTGTTGCATATTC
H121 TCTTTTATCTAAGGCGAGATCATCGTCGCCTTCTTTAC
T41R ATCGGTCGACTTAATTGTTTTTTTTTATTGG
T42R ATCGGTCGACTTAATCATCGTCGCCTTCTTTAC
T43R ATCGGTCGACTTACTCTTCTGTTGCATATTC
T44R ATCGGTCGACTTAAAAAGCCCAACCAAGAGAG
T45R ATCGGTCGACTTAGTCGCCAGATTTATCTTCC
H165 ATCGGTCGACTTAGTCGCCAGATTTATCTTCC
H310 GGTGACGATGACGATAAGTCTGTGAGTGAAATACAGC
H311 CACTCCGTTCAAGTCGACTTACTGGGATTTAGCTTTAG
H410 GGTGACGATGACGATAAGAACTCCGACTCCGAGTGTC
H616 CTCGCCTTAGATAAAAGAAACTCCGACTCCGAGTGTC
H617 ACCAAGAGAGTTAATAACTCATCTCAGCTCCCACCAC
H618 CATCGTCACCGTGGTGATGGTGATGATGGCTCAAAGTCTCTTCTG
H619 TCACCACGGTGACGATGACGATAAGAACTCCGACTCCGAGTGTC
H620 GTCACCATCTTCATCTTCTCTTTTATCTAAGGCGAGG
H621 CCTCGCCTTAGATAAAAGAGAAGATGAAGATGGTGAC
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to the HL-peptide was purified by metal affinity chromatog-
raphy on a nickel-NTA agarose column (Promega,Wisconsin,
USA) using medium pressure liquid chromatography (Bio-
Rad). Fermentation broth was filtered with a 0.1-μm
Sartoclear filter (Sartorius, Goettingen, Germany), and con-
centrated by ultrafiltration with 10 K NMWC Quick-stand
(Amersham-Pharmacia Biotech, Piscataway, NJ USA) using
buffer A [50 mM Tris-HCl (pH 8.0), 0.5 M NaCl]. The con-
centrated solution was loaded onto the column at a flow rate of
1 ml/min and proteins were eluted in a gradient of buffer B
[50 mM Tris-HCl (pH 8.0), 0.5 M NaCl, 0.5 M imidazole].
The fractions containing proteins of interest were concentrat-
ed, and buffer B was replaced with EK buffer [20 mM Tris-
HCl (pH 8.0), 50 mM NaCl, and 2 mM CaCl2] by ultrafiltra-
tion with 10 K MWCO Amicon Ultra centrifugal filter device
(Millipore, Massachusetts, USA). To remove the HL peptide
from the fused protein, enterokinase (Invitrogen, USA) was
added to the protein solution (one unit per mg of fused protein)
and incubated at 16 °C for 15 h. The intact hEGF protein was
obtained by repeating metal affinity chromatography on the
nickel-NTA agarose column using medium pressure liquid
chromatography. The molecular weight of the purified hEGF
protein was determined by using a 4700 Proteomic Analyzer
(Applied Biosystems, Framingham, MA, USA) at Korea
Basic Science Institute (Daejeon, Korea). The bioactivity of
hEGF was determined with a lymphocyte proliferation assay
using the EL-4 mouse T-lymphocyte cell line and a Cell
Proliferation ELISA, BrdU kit (Roche, Germany).
Results
Determination of the optimal VOA1 fragment
for extracellular secretion
Voa1p is an ERmembrane protein that is postulated to be one of
five V0 assembly factors for vacuolar ATPase (Ryan et al. 2008).
Voa1p consists of 265 amino acids containing a secretion signal
peptide, three glycosylation sites, a proposed hydrophilic domain
(HL), and a transmembrane domain (TM) (Fig. 1a). In normal
conditions, this protein is retained in the ER membrane but a C-
terminally truncated partial Voa1p (213 amino acids) was secret-
ed into the culture medium at high levels when expressed under
control of the GAL10 promoter.
To determine the optimal domains required for secretion of
Voa1p, we expressed five incremental C-terminal deletion mu-
tants in yeast under the control of a GAL10 promoter. As shown
in Fig. 1, no proteins were detected in the culture supernatant of
the YGaT41 strain expressing full-length Voap1 (Fig. 1c, lane 1).
In contrast, a high amount of truncated VOA1 protein was secret-
ed from cells expressing YGaT42, YGaT43, and YGaT44
(Fig. 1c, lanes 2–4). The Voa1p derivatives were visible as two
bands due to glycosylation events. This was confirmed by the
disappearance of the higher molecular weight band and concom-
itant increased intensity of the low molecular weight band fol-
lowing treatment with the Endo-H glycosylase (data not shown).
Interestingly, further truncation of the Voa1p sequence in
YGaT45 (which encodes a protein with no HL domain and
removes a glycosylation site), did abrogated secretion of the
protein. From these data, we conclude that hypersecretion of
Voa1p, is facilitated by removal of the TM domain, and is to
some extent dependent on the structural portion of Voa1p that
contains all three glycosylation sites.
Utilization of Voa1p derivatives as a fusion partner
To test Voa1p derivatives as fusion partners that could improve
the secretion of otherwise poorly secreted heterologous proteins
from yeast, we selected human interleukin-2 (hIL2). First, the
hIL2 gene was fused to the ends of the Voa1p derivatives
encoded in the YGaT42, YGaT43, andYGaT44 vectors. Ayeast
dipeptidyl protease Kex2p recognition sequence (Leu-Asp-Lys-
Arg) was added between Voa1p derivatives and hIL2 to facilitate
in vivo processing (Mizuno et al. 1988). Schematic diagrams of
each fusion gene construct are shown in Fig. 2a. After cultivation
of each recombinant strain, concentrated culture supernatants and
intracellular fractions were analyzed using SDS-PAGE and
Western blotting, respectively (Fig. 2b, c). Two bands corre-
sponding to C-terminally truncated Voa1p and correctly proc-
essed hIL2 were identified in the cases of YGaT42-IL2 and
YGaT43-IL2, respectively (Fig. 2b, lanes 1 and 2). Both vectors
contained at least some hydrophilic residues of the Voa1p HL
domain. In contrast, no Voa1p or hIL2 bands were observed
following induction of YGaT44-IL2, which encodes a variant
that completely lacks hydrophilic residues of the HL domain
(Fig. 2b, lane 3). In intracellular fraction, unprocessed Voa1p-
hIL2 fusion protein bands were detected in all cases but proc-
essed hIL2 bands were detected only in the cases of YGaT42-
IL2 and YGaT43-IL2 (Fig. 2c, lanes 1 and 2). Therefore, fusion
protein fromYGaT44-IL2may not reach the Golgi complex and
would be gradually degraded by the ER quality control system.
The HL domain was not crucial for the secretion of C-terminally
truncated Voa1p fromYGaT44 (Fig. 1c, lane 4). However, in the
context of the C-terminally truncated Voa1p and hIL2 fusion
protein, hydrophilic residues of the HL domain was critical for
secretion. As shown in Fig. 2b, c, hIL2 proteins was hardly
detected in extra and intracellular fraction without the HL do-
main. Thus, we conclude that the HL domain improves the sol-
ubility of fusion proteins in the ER, and thus facilitates trafficking
between ER and Golgi complex.
Utilization of HL domain as a fusion peptide to improve
the solubility of target proteins
Based on the above-mentioned results, we hypothesized that
acidic amino acids within the HL domain might contribute to
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the increased secretion of proteins, since the solubility of a
protein is closely related to its net charge (Zhang et al. 2004)
(Trevino et al. 2007). For general application, a metal affinity
purification tag and an EK recognition sequence were added
to the end of HL peptide resulting HL50. To further investi-
gate the positional effects of the HL domain, we fused HL50
to either the N-terminus or C-terminus of human epidermal
growth factor (hEGF) (YEGα-HL50-EGF and YEGα-EGF-
HL50), respectively (Fig. 3a). To focus on the effects of HL
domain, secretion of HL50-tagged hEGF was controlled by a
generally used yeast secretion signal (the mating factor α pre-
pro peptide) instead of Voa1p signal. As shown in Fig. 3b, N-
terminal tagging of hEGF with HL50 improved the secretion
of fusion proteins (Fig. 3b, lane 2) ~10-fold compared to un-
tagged proteins (Fig. 3b, lane 1). On the other hand, hEGF
tagged with HL50 at the C-terminus was poorly secreted
(Fig. 3b, lane 3). Use of the N-terminal HL peptide tag is also
desirable as it facilitates the removal of tags from fusion pro-
teins. This is since commonly used tags are cleaved by
sequence-specific endoproteases such as EK, TEV, and
1     2    3    4    5   M   
(C)(B)
YGaT41
YGaT42
YGaT43
YGaT44
YGaT45
N            N          N HL TMsig
N            N          N HLsig
N            N          Nsig
N            N          Nsig
N            N  sig
17kDa
16kDa
34kDa
45kDa
(A)
MVFGQLYALFIFTLSCCISKTVQADSSKESSSFISFDKESNWDTISTISS  50
TADVISSVDSAIAVFEFDNFSLLDNLMIDEEYPFFNRFFANDVSLTVHDD 100
SPLNISQSLSPIMEQFTVDELPESASDLLYEYSLDDKSIVLFKFTSDAYD 150
LKKLDEFIDSCLSFLEDKSGDNLTVVINSLGWAFEDEDGDDEYATEETLS 200
HHDNNKGKEGDDDILSSIWTEGLLMCLIVSALLLFILIVALSWISNLDIT 250
YGALEKSTNPIKKNN
Signal sequence
HL domain
TM domain
T45 T44 T43
T42
T41
Fig. 1 Expression analysis of
C-terminally truncated VOA1
derivatives. a The predicted
amino sequence and domains
encoded by the VOA1 gene.
Truncation sites are indicated by
arrows. Glycosylation sites are
highlighted in bold. b Schematic
diagram of serially deleted VOA1
genes. Sig signal peptide, N N-
linked glycosylation site, HL
hydrophilic domain, TM:
transmembrane domain. c
Expression levels of VOA1
derivatives were analyzed by
SDS-PAGE. Lanes 1–5 culture
broth of S. cerevisiae transformed
with YGaT41–YGaT45 vector,
respectively; lane M pre-stained
protein size marker (Invitrogen)
1      2     3     4
Voa1p
hIL2
(A)                       (B)                            (C)
17kDa
16kDa
34kDa
45kDa
YGaT42-IL2
YGaT43-IL2
YGaT44-IL2
N      N   N HLsig
N       N   Nsig
N       N   Nsig
hIL2
KEX2
hIL2
KEX2
hIL2
KEX2
7kDa
1      2     3     
Voa1-hIL2
hIL2
Fig. 2 Expression analysis of VOA1 derivatives fused with hIL2. a
Schematic representation of VOA1-hIL2 fusion proteins. Sig signal
peptide, N N-linked glycosylation site, HL hydrophilic domain. b
Confirmation of hIL2 expression by SDS-PAGE analysis. Lanes 1–3
culture broth of S. cerevisiae transformed with YGaT42-IL2, YGaT43-
IL2, and YGaT44-IL2 vector, respectively; lane M pre-stained protein
size marker (Invitrogen). cWestern blot analysis of intracellular proteins.
Lanes 1–3 cell extract of recombinant strains carrying YGaT42-IL2,
YGaT43-IL2, and YGaT44-IL2 vector, respectively
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Factor Xa that cleave after their recognition sites; thus, N-
terminal tags are removed without leaving residual peptides
on the target proteins.
Engineering of HL peptide as a general fusion tag
To optimize the HL peptide as a general fusion tag, three HL
variant peptides, HL50, HL37, and HL28, were tested for their
ability to promote hEGF secretion. As shown in Fig. 4a, the
HL50 construct contains a metal affinity purification tag and
EK recognition sequence (HHHHHHGDDDDK) at the end of
the HL peptide. For HL37, 11 amino acids of the HL peptide
(DNNKGKEGDDD) were replaced with 10 amino acids
(HHHHGDDDDK). To minimize the size of HL domain
without altering its net charge, nine nonpolar amino acids
(VINSLGWAF) located at the N-terminus of HL37 were re-
moved in order to yield construct HL28. According to the
positional preference (Fig. 3), the three HL variants were
fused to the N-terminus of hEGF, and the MF α pre-pro pep-
tide was added to promote secretion of all fused proteins. The
secretion-enhancing effect of the HL variant peptide was still
maintained after modification (Fig. 4c, lane 3) and truncation
(Fig. 4c, lane 4). Because there are no possible glycosylation
sites in the HL50 peptide or hEGF, we infer that the high
molecular weight smear bands formed by YEGα-HL50-
EGF and YEGα-HL37-EGF (Fig. 4c, lanes 2, 3) were due
to hyper-glycosylation of incompletely processed MF α pro
peptide. To confirm the presence of hyper-glycosylation, se-
creted fusion proteins were re-analyzed after treatment with
Endo-H (Fig. 4c, lanes 5–8). As expected, unprocessed fusion
bands appeared after deglycosylation in YEGα-HL50-EGF
and YEGα-HL37-EGF (Fig. 4c, lanes 6, 7). However, neither
incomplete processing by Kex2p nor hyper-glycosylation
were found in the case of YEGα-HL28-EGF, suggesting that
removal of nine nonpolar amino acids (VINSLGWAF) facil-
itated complete processing of HL28-hEGF by Kex2p (Fig. 4c,
lane 8). To test the susceptibility of each HL peptide to in vitro
endoprotease digestion, secreted fusion proteins were treated
with EK. In contrast to the HL50-hEGF and HL37-hEGF
fusion proteins, which were poorly digested (Fig. 4c, lanes
10 and 11), about 80 % of HL28-hEGF was digested, yielding
intact hEGF (Fig. 4c, lane 12). These results clearly demon-
strate that HL28 is a good candidate as a general fusion pep-
tide for secretory expression of heterologous proteins.
Characterization of yeast recombinant hEGF
A recombinant Y2805 strain harboring YEGα-HL28-EGF
was cultured in a 5-l jar fermenter under fed-batch fermenta-
tion conditions. Samples were taken over a 48-h culture period
and supernatants were analyzed by SDS-PAGE (Fig. 5a, b).
Using hEGF produced by E. coli as a standard, the amount of
secreted HL28-hEGF fusion protein was ~400 mg/l. The
HL28-hEGF fusion protein was first directly purified by Ni-
NTA affinity chromatography (Fig. 5c, lane 2). Following
removal of HL28 using EK digestion, intact hEGF was puri-
fied by Ni-NTA affinity chromatography (Fig. 5c lane 3). N-
terminal amino acid sequencing and mass analysis confirmed
that the purified hEGF was intact (data not shown). The bio-
logical activities of purified intact hEGF and HL28-fused
hEGF were characterized using an in vitro proliferation assay.
Both constructs had growth-stimulating activity comparable
to that of commercial hEGF produced in E. coli (Fig. 5d). This
suggests that the biological activity of hEGF is not perturbed
by N-terminal fusion of HL28.
Application of HL28 to enhance protein secretion
We next selected two poorly secreted, but pharmaceutically
important proteins to test the ability of the HL28 peptide to
enhance secretion. Exendin-4 (EXD-4), a glucagon-like pep-
tide-1 receptor agonist used for the treatment of type 2 diabe-
tes, and human insulin-like growth factor type 1 (hIGF-1),
which is used to treat type 1 and 2 diabetes were expressed
under fusion with or without HL28 peptide. Secretion of re-
combinant proteins was ensured by expression of the MF α
pre-pro peptide under the control ofGAL10 promoter (Fig. 6).
EXD-4 was not detected in the culture supernatant when
expressed without HL28 (Fig. 6, lane 1) but an obvious pro-
tein band corresponding to the expected size (7.4 kDa) of the
fusion protein was formed after tagging the N-terminus of
EXD-4 with HL (Fig. 6, lane 2). Similarly, HL28 fusion ro-
bustly increased secretion of hIGF-1 compared to untagged
hIGF-1 (Fig. 6, lanes 3 and 4). These data strongly suggest that
the HL28 peptide will find utility in the production of poorly
secreted recombinant proteins in yeast, and will also enhance
production and simplify the process of protein purification.
1
2
3
MF pre-pro HL50 hEGF
KEX2
MF pre-pro hEGF
KEX2
MF pre-pro HL50hEGF
KEX2
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Fig. 3 Effects of HL50 tagging on the expression of hEGF. a Schematic
representation of the hEGF secretion cassette. b SDS-PAGE analysis of
culture broth of S. cerevisiae transformed with YEGα-EGF (lane 1),
YEGα-HL50-EGF (lane 2), and YEGα-EGF-HL50 (lane 3),
respectively; lane M pre-stained protein size marker (Invitrogen)
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Fig. 5 Confirmation of recombinant hEGF expression. a Time profiles
of fed-batch fermentation of S. cerevisiae expressing YEGα-HL28-EGF.
b SDS-PAGE analysis of culture supernatants. Samples of culture
supernatants (10 μl) at the indicated times were analyzed. c SDS-PAGE
of the purified hEGF. Lane 1 after ultrafiltration of fermentation broth,
lane 2 after Ni-NTA affinity chromatography, and lane 3 purified hEGF
after EK digestion. d Bioactivity assay of the purified hEGF. The EL-4
cell line was cultured in the presence of the indicated amounts of hEGF,
and cell proliferation was analyzed following bromodeoxyuridine (BrdU)
labeling
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Fig. 4 Expression of hEGF using
modified HL peptides. a Amino
acid sequence of modified HL
peptides. b Schematic
representation of the hEGF
secretion cassette. c SDS-PAGE
analysis of culture broth of
S. cerevisiae transformed with
YEGα-EGF (lanes 1, 5, 9);
YEGα-HL50-EGF (lanes 2, 6,
10); YEGα-HL37-EGF (lanes 3,
7, 11); and YEGα-HL28-EGF
(lanes 4, 8, 12); respectively.
Lanes 5–8 after deglycosylation,
lanes 9–12 after digestion with
EK, lane M pre-stained protein
size marker (Invitrogen)
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Discussion
A generally preferred method for enhanced secretion and ef-
ficient purification of recombinant proteins is to express them
with fusion partners. There have been numerous reports on the
development and application of fusion tags (Kang et al. 2007),
(Huang et al. 2008),(Kajino et al. 2000), (Sievi et al. 2003),
(Ahn et al. 2004), (Andres et al. 2005). In this regard, we
developed a novel fusion partner by using the S. cerevisiae
ER membrane protein, Voa1p. In a previous report (Bae et al.
2015), we discovered that Voa1p is secreted at high levels
(grams per liter) into the extracellular medium by
S. cerevisiae when the TM domain was removed. Therefore,
we expected that the truncated protein would have great po-
tential as a fusion partner for soluble expression of target pro-
teins in S. cerevisiae. Although high molecular weight fusion
partners such as human serum albumin are widely used, low
molecular weight fusion partners are usually preferred for
economic reasons, since the smaller fusion partner requires
less cellular resources and reduces the burden for the host cell.
Here, we identified a hydrophilic peptide (HL peptide)
consisting of 28 amino acid that is responsible for the im-
provement of target protein secretion. The original HL peptide
contained high portion of charged amino acids (14 acidic ami-
no acids and 4 basic amino acids) and modified HL peptide
contained more charged amino acids (13 acidic amino acids
and 7 basic amino acids) owing to six histidine and EK cleav-
age sites. Since the HL28 peptide is not large enough to as-
sume significant tertiary structure, we infer that its ability to
enhance secretion of fusion proteins is due to the high portion
of charged amino acids, rather than the overall conformation
of the peptide.
A large net negative charge increases protein solubility by
increasing electrostatic repulsion forces between nascent pro-
teins (Zhang et al. 2004) (Trevino et al. 2007). Consistent with
this, the net negative charges of hEGF (−3.9 at pH 7.0), EXD-
4 (−2.9), and hIGF-1 (0.7) increased to −14.9, −13.8, and
−10.25 by addition of HL28, respectively. Therefore, modifi-
cation of passenger protein net negative charge may increase
secretion efficiency by affecting to protein solubility in the
ER, or by altering trafficking to Golgi.
In addition to the proteins reported in the BResults^ section,
HL peptide was further applied to the expression of other clini-
cally relevant proteins, such as human parathyroid hormone
(hPTH) and immunoglobulin (Ig). Fusion of HL28 to the N-
terminus of hPTH increased expression about fivefold, but did
not alter the amount of Ig secretion (data not shown). We also
applied the HL28 peptide for the expression of highly expressed
industrial proteins, such as lipase B from Candida antarctica
(CalB) and cellobiohydrolase 1 (CBH1) from Trichorderma
reesei in order to further increase the expression of these proteins.
As in the case of Ig, the expression of these proteins was not
affected by HL28 tagging. Considering the likely mechanism of
action for the HL28 peptide, these results were expected.
Because HL28 peptide increases the secretion of passenger pro-
teins by increasing the net negative charge of fused proteins, the
net charge of large proteins such as Ig,CalB, andCBH1 is hardly
affected byHL28-taggingwhen compared to small proteins such
as hEGF, hIGF-1, and EXD-4.
Although both N-terminal and C-terminal fusion partners can
be used with heterologous proteins, N-terminal tagging is more
favorable for downstream processes such as endoprotease treat-
ment and protein purification. In most of the tested cases, the
secretion-enhancing effect of the HL28 peptide was clearly de-
pendent on the tagging position. AlthoughN- andC-terminal HL
tags increased the net negative charge of fusion proteins to a
similar degree, N-terminal fusions were more robustly secreted.
Therefore, we believe that, in addition to altering net charge,
there are other properties of HL28 that affect folding and traffick-
ing of passenger proteins.
In summary, we have developed a novel fusion partner that
enhances the secretion of fused proteins and simplifies the
purification process. This system will be useful for secretory
production of heterologous proteins (particularly small pep-
tide proteins) in S. cerevisiae.
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